Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase

Chinese Medical Journal

Volumn 122, Issue 20, 2009, Pages 2466-2471

  Sun, Hui Ming ^a   Hong, Ling Zhi ^a   Shen, Xiao Kun ^a   Lin, Xin Qing ^a   Song, Yong ^a   Shi, Yi ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Acute lung injury; Antithrombin iii; Endotoxin; Heparin; Mitogen activated protein kinase

Indexed keywords

ANTITHROMBIN III; ENDOTOXIN; HEPARIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; LUNG BLOOD VESSEL; MALE; MONOTHERAPY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTITHROMBIN III; ENDOTOXINS; HEPARIN; LUNG; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70350714610     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.20.013     Document Type: Article

References (28)

1. Murakami K, McGuire R, Cox RA, Jodoin JM, Schmalstieg FC, Traber LD, et al. Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep. Crit Care Med 2003; 31: 577-583. (Pubitemid 36232958)
2. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
3. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of antithrombin-III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10: 90-96. (Pubitemid 128463839)
4. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 2005; 31: 1101-1108. (Pubitemid 41125342)
5. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al; KyberSept Trial Study Group. Caring for the critically ill patient. High dose antithrombin-III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.
6. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Brieqel J, et al. High-dose antithrombin-III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292. (Pubitemid 43145602)
7. Carter AB, Monick MM, Hunninghake GW. Both Erk and P38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 1999; 20: 751-758.
8. Kim HJ, Lee HS, Chong YH, Kang JL. P38 mitogen-activated protein kinase up-regulates LPS-induced NF-kappa B activation in the development of lung injury and RAW 264.7 macrophages. Toxicology 2006; 225: 36-47.
9. Smith KM, Mrozek JD, Simonton SC, Bing DR, Meyers PA, Connett JE, et al. Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory distress syndrome. Crit Care Med 1997; 25: 1888-1897.
10. Rezaiguia S, Garat C, Delclaux C, Meignan M, Fleury J, Legrand P, et al. Acute bacterial pneumonia in rats increases alveolar epithelial fluid clearance by a tumor necrosis factor alpha-dependent mechanism. J Clin Invest 1997; 99: 325-335. (Pubitemid 27053472)
11. Qiu HB, Lu XM, Zhou SX, Yang Y, Guo FM. Effect of high tidal volume ventilation and lipopolysaccharide on mitogen-activated protein kinase in rat lung tissue. Chin Med J 2006; 119: 53-56.
12. Matthay MA. Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 2001; 344: 759-762.
13. Feistritzer C, Wiedermamm CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007; 7: 855-870. (Pubitemid 46954432)
14. Rehberg S, Enkhbaatar P, Traber DL. Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction? Crit Care 2008; 12: 179.
15. Kalsch T, Elmas E, Nguyen XD, Suvajac N, Kluter H, Borggrefe M, et al. Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 2007; 102: 460-466.
16. Hack CE, Zeerleder S. The endothelium in sepsis: Source of and a target for inflammation. Crit Care Med 2001; 29: S21-S27.
17. Hagiwara S, Iwasaka H, Matsumoto S, Noquchi T. High dose antithrombin-III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 2008; 34: 361-367. (Pubitemid 351207646)
18. Davidson BL, Geerts WH, Lensing AW. Low dose heparin for severe sepsis. N Engl J Med 2002; 347: 1036-1037.
19. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003; 31: 1108-1112.
20. Bernard GR, Vincent JL, Laterre PF, Larosa SP, Dhainaut JF, Lopezrodriquez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated human protein C for severe sepsis. New Engl J Med 2001; 344: 699-709.
21. Abraham E, Reinhart K, Opal S, Demeyer I, Doiq C, Rodriquez AL, et al. OPTIMIST Trial Study Group. Efficacy and safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in severe sepsis. JAMA 2003; 290: 238-247.
22. Lin HY. Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects. Chin Crit Care Med (Chin) 2007; 19: 134-137.
23. Cornet AD, Smit M, Beishuizen A, Groeneveld J. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98: 579-586. (Pubitemid 47412883)
24. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-252. (Pubitemid 34873705)
25. Kaneider N, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003; 90: 1150-1157. (Pubitemid 38004437)
26. Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care 2006; 10: 209-218.
27. Ren XS, Qiao YJ, Xia XH, Xu J, Jia HY. Effects of antithrombin-III on cytokines in rats with multiple organ dysfunction syndrome. Chin Crit Care Med (Chin) 2005; 17: 565-567.
28. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, et al. Antithrombin-III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-4020.